CN105815658A - Milk basic protein ferroporphyrin composite piece and preparing method thereof - Google Patents
Milk basic protein ferroporphyrin composite piece and preparing method thereof Download PDFInfo
- Publication number
- CN105815658A CN105815658A CN201610181004.3A CN201610181004A CN105815658A CN 105815658 A CN105815658 A CN 105815658A CN 201610181004 A CN201610181004 A CN 201610181004A CN 105815658 A CN105815658 A CN 105815658A
- Authority
- CN
- China
- Prior art keywords
- parts
- basic protein
- milk basic
- ferroporphyrin
- milk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013336 milk Nutrition 0.000 title claims abstract description 32
- 239000008267 milk Substances 0.000 title claims abstract description 32
- 210000004080 milk Anatomy 0.000 title claims abstract description 32
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 title claims abstract description 30
- 239000002131 composite material Substances 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title abstract description 5
- 239000000314 lubricant Substances 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 8
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims abstract description 7
- 229940069338 potassium sorbate Drugs 0.000 claims abstract description 7
- 235000010241 potassium sorbate Nutrition 0.000 claims abstract description 7
- 239000004302 potassium sorbate Substances 0.000 claims abstract description 7
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 3
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 3
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 3
- -1 ferrous porphyrin Chemical class 0.000 claims description 42
- 238000002360 preparation method Methods 0.000 claims description 15
- 238000007906 compression Methods 0.000 claims description 6
- 230000006835 compression Effects 0.000 claims description 6
- 238000007908 dry granulation Methods 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 241001502050 Acis Species 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 2
- 235000011037 adipic acid Nutrition 0.000 claims description 2
- 239000001361 adipic acid Substances 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 229910052710 silicon Inorganic materials 0.000 claims description 2
- 239000010703 silicon Substances 0.000 claims description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 2
- 241000590002 Helicobacter pylori Species 0.000 abstract description 14
- 229940037467 helicobacter pylori Drugs 0.000 abstract description 14
- 235000003891 ferrous sulphate Nutrition 0.000 abstract description 9
- 239000011790 ferrous sulphate Substances 0.000 abstract description 9
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 abstract description 9
- 229910000359 iron(II) sulfate Inorganic materials 0.000 abstract description 9
- 239000000047 product Substances 0.000 abstract description 9
- 239000013589 supplement Substances 0.000 abstract description 8
- 210000004369 blood Anatomy 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 6
- 230000001502 supplementing effect Effects 0.000 abstract description 6
- 235000013305 food Nutrition 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 2
- 102000008857 Ferritin Human genes 0.000 abstract 1
- 108050000784 Ferritin Proteins 0.000 abstract 1
- 238000008416 Ferritin Methods 0.000 abstract 1
- 230000037213 diet Effects 0.000 abstract 1
- 235000005911 diet Nutrition 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 239000002075 main ingredient Substances 0.000 abstract 1
- 238000009736 wetting Methods 0.000 abstract 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 33
- 239000007910 chewable tablet Substances 0.000 description 12
- 229940068682 chewable tablet Drugs 0.000 description 12
- 229910052742 iron Inorganic materials 0.000 description 12
- 102000001554 Hemoglobins Human genes 0.000 description 10
- 108010054147 Hemoglobins Proteins 0.000 description 10
- 208000007502 anemia Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 8
- 229960001781 ferrous sulfate Drugs 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 101000798100 Bos taurus Lactotransferrin Proteins 0.000 description 5
- 229940072440 bovine lactoferrin Drugs 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 102000010445 Lactoferrin Human genes 0.000 description 3
- 108010063045 Lactoferrin Proteins 0.000 description 3
- 206010000059 abdominal discomfort Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229940078795 lactoferrin Drugs 0.000 description 3
- 235000021242 lactoferrin Nutrition 0.000 description 3
- 235000021590 normal diet Nutrition 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 206010022971 Iron Deficiencies Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241001420686 Hypochrosis Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- MDXRFOWKIZPNTA-UHFFFAOYSA-L butanedioate;iron(2+) Chemical compound [Fe+2].[O-]C(=O)CCC([O-])=O MDXRFOWKIZPNTA-UHFFFAOYSA-L 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229940085513 feosol Drugs 0.000 description 1
- 229960000225 ferrous fumarate Drugs 0.000 description 1
- 235000002332 ferrous fumarate Nutrition 0.000 description 1
- 239000011773 ferrous fumarate Substances 0.000 description 1
- 239000004222 ferrous gluconate Substances 0.000 description 1
- 229960001645 ferrous gluconate Drugs 0.000 description 1
- 235000013924 ferrous gluconate Nutrition 0.000 description 1
- 229960001604 ferrous succinate Drugs 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 150000004032 porphyrins Chemical group 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a milk basic protein ferroporphyrin composite piece and a preparing method thereof.The main ingredients comprise milk ferritin and ferroporphyrin.The composite piece is prepared from, by weight, 1-10 parts of milk basic protein, 1-20 parts of ferroporphyrin, 1-5 parts of maltodextrin, 1-5 parts of potassium sorbate and 1-5 parts of a lubricating agent.The milk basic protein is extracted from milk.Ferroporphyrin is extracted from pig blood.The materials are sheeted through a drying method or granulated and sheeted through a wetting method to obtain the composite piece.Compared with common ferrous sulfate supplement and ferroporphyrin supplement, the fer supplementing effect is promoted obviously; meanwhile, the composite piece can effectively remove helicobacter pylori of the human body.The composite piece is prepared from the natural food materials, can serve as diet therapy healthcare product to be taken for a long term, while fer is supplemented effectively and safely, human body immunity is improved, and the function of removing helicobacter pylori is achieved.
Description
Technical field
The invention belongs to technical field of health care food, be specifically related to a kind of milk basic protein ferrous porphyrin composite sheet that can improve iron deficiency anemia, removing helicobacter pylori, raising body immunity and preparation method thereof.
Background technology
Ferrum is the trace element of needed by human, is the metabolic basis maintaining cell, synthesis participating in the duplication of DNA, the transmission of electronics, hemoglobin and various oxidoreductase etc. process.The internal iron deficiency that ferrum incomplete absorption causes can cause multiple common disease；But the excess of ferrum will also result in toxic action to human body, ferrum build up generation reactive oxygen free radical, free radical can cause again the oxidation of albumen and cell membrane lipid, the damage of DNA, ultimately results in the apoptosis of cell.Therefore mammal is during evolution, forms a set of tight regulatory mechanism, the absorption of regulation and control ferrum and transhipment, maintains internal iron balance.Iron content in the women body grown up is about 3g, and the iron content in males is about 4g.The ferrum that needed by human body is wanted mainly is provided by macrophage, macrophage phagocytic and the erythrocyte of decomposition aging, the ferrum about 20-30mg that every day produces, it is possible to be released re-using.Human body needs the ferrum from Absorption in vitro to be only 1-2mg.Iron deficiency anemia (IDA) refers to the internal storage iron deficiency that may be utilized in fabricating hemoglobin, hemoglobin synthesizes a kind of minicell, the hypochrosis reduced and cause, being modal a kind of anemia, women (particularly anemia of pregnant woman) and infant morbidity with the childbearing age are higher.
Main iron supplementary is divalent iron salt.Common medicine has ferrous sulfate, Ferrous gluconate, ferrous fumarate and ferrous succinate, and absorbance is relatively low, and stomach discomfort when many existence are taken.As a example by the ferrous sulfate being most widely used, 17th century end starts to be people and is utilized for preventing and treating anemia, because its taking convenience is respond well at present also widely used.But the inorganic chalybeate such as ferrous sulfate has the shortcoming being difficult to be absorbed by the body, because the easily oxidation in the acid solutions such as gastric acid of these inorganic chalybeates generates rust, thus adhere to gastrointestinal mucosa and produce the more serious stimulation of ratio, cause the symptoms such as Nausea and vomiting, and absorbtivity is relatively low, generally 1-3%.
For the deficiency of ferrous sulfate etc. patch supplementing preparation, people start with ferrous porphyrin and prevent and treat anemia.The principle of enriching blood of ferrous sulfate is that ferrous sulfate dissociates in human body, thus completes the process of hemopoietic.Ferrous porphyrin is the porphyrin compound being made up of the iron ion of a porphyrin ring and a positive bivalence, separation and Extraction from Sanguis sus domestica, is directly combined generation hemoglobin after absorption of human body with globin, and enriching blood certainly will be the most how.Additionally, molecular structure quite stable due to ferrous porphyrin, will not be dissociated in vivo, thus absorption rate is high, general more than 25%, having no stimulation human body, and avoid ferrous sulfate the stimulation to human body occurs after oxidation reaction in human body, what is more important avoids sulfate ion may put aside the side effect of poisoning in vivo.But it is poor that existing ferrous porphyrin preparation there is also certain defect, such as mouthfeel, and groups of people are had after taking, to there will be the symptom of stomach discomfort.
Additionally, research finds that helicobacter pylori competitiveness can absorb divalent Fe in stomach, thus affect the human body normal absorption to ferrum.General iron deficiency anemia iron supplement can be absorbed by supplementary chalybeate, but for helicobacter pylori positive patient, absorbability is the most very poor, helicobacter pylori to be removed, the most again iron supplement.
The application i.e. finds one's way out for above-mentioned condition.
Summary of the invention
In order to overcome the deficiencies in the prior art, make up the defect that existing ferrum supplementing preparation exists, the invention discloses a kind of milk basic protein ferrous porphyrin composite sheet and preparation method thereof, also there is while highly effective and safe iron supplement the effect increasing body immunity, removing helicobacter pylori, improve the efficiency of iron supplement further.
In order to realize foregoing invention purpose, the technical solution used in the present invention is as follows:
A kind of milk basic protein ferrous porphyrin composite sheet, it is characterised in that main component includes milk basic protein and ferrous porphyrin.
Further, in parts by weight, including milk basic protein 1 10 parts, ferrous porphyrin 1 20 parts, maltodextrin 15 parts, potassium sorbate 15 parts, lubricant 15 parts.
Described milk basic protein is for purchasing finished product.
Described ferrous porphyrin is for purchasing finished product.
Described lubricant is selected from one or more in Pulvis Talci, sodium stearate, magnesium stearate, adipic acid, esters of silicon acis, phosphate ester.
The preparation method of above-mentioned milk basic protein ferrous porphyrin composite sheet, uses compressing dry granulation or wet granule compression tablet to prepare.
Milk basic protein is organically combined by the present invention with ferrous porphyrin, solve the milk prohibitively expensive function singleness of basic protein price, and ferrous porphyrin mouthfeel difference takes the defect that may cause stomach discomfort, the assimilation effect multiple function for the treatment of helicobacter pylori, raising patient's immunity and then enhancing chalybeate is combined, makes up the defect of above-mentioned single product.Beneficial effects of the present invention is mainly manifested in the following aspects: 1, use ferrous porphyrin and milk basic protein as main supplements-iron, absorption rate is high, and there is no the side effect of the most common ferrum supplementing preparation, for preventing and treating iron deficiency anemia, there is good efficacy；2, the milk basic protein that the present invention adds is rich in Bovine Lactoferrin, lactoferrin therein also has the several functions such as antibacterial, antiviral, anticancer and regulation organism immune response, lactoferrin can be with Multiple Classes of Antibiotics and antiviral drugs synergism, reduce drug dose, reduce antibiotic or the infringement to human body Liver and kidney function of the disease-resistant fungi preparation, strengthen the internal microorganism sensitivity to medicine simultaneously, also have obvious curative effect for removing helicobacter pylori；3, the compositions of the present invention utilizes natural food materials to make, and as a kind of food therapeutic health long-term taking human body can will not produce harmful effect, and meets Vehicles Collected from Market to pure natural health-care product and the trend of medicine, therefore has good market prospect.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention made further explanation explanation.
Embodiment 1
A kind of chewable tablet treating iron deficiency anemia, is made up of the material of following parts by weight: include Bovine Lactoferrin 2 parts, ferrous porphyrin 18 parts, sucrose 5 parts, potassium sorbate 3 parts, lubricant 2 parts, using compressing dry granulation or wet granule compression tablet to make chewable tablet, every 2g, for finished product.
Embodiment 2
A kind of chewable tablet treating iron deficiency anemia, is made up of the material of following parts by weight: include Bovine Lactoferrin 4 parts, ferrous porphyrin 16 parts, sucrose 4 parts, potassium sorbate 3 parts, lubricant 3 parts, using compressing dry granulation or wet granule compression tablet to make chewable tablet, every 2g, for finished product.
Embodiment 3
A kind of chewable tablet treating iron deficiency anemia, is made up of the material of following parts by weight: include Bovine Lactoferrin 6 parts, ferrous porphyrin 14 parts, sucrose 4 parts, potassium sorbate 3 parts, lubricant 3 parts, using compressing dry granulation or wet granule compression tablet to make chewable tablet, every 2g, for finished product.
Embodiment 4
A kind of chewable tablet treating iron deficiency anemia, is made up of the material of following parts by weight: include Bovine Lactoferrin 8 parts, ferrous porphyrin 14 parts, sucrose 4 parts, potassium sorbate 2 parts, lubricant 2 parts, using compressing dry granulation or wet granule compression tablet to make chewable tablet, every 2g, for finished product.
Embodiment 5
Milk basic protein ferrous porphyrin composite sheet of the present invention is as the experiment of rat serum supplementing preparation.
Buy rat 30 after wean, average weight 60g, be divided into three groups, often group 10.Method for breeding: experimental group feeds normal diet and adds the milk basic protein ferrous porphyrin composite sheet 2g(mono-group use 2g of embodiment 1 preparation, lower same), control group fed normal diet adds Feosol 2g, blank group feeds normal diet, the Blood Hemoglobin Concentration of rat is detected after feeding continuously 2 months, in blank group, matched group and interpolation lactoferrin ferrous porphyrin composite sheet group, rat hemoglobin mean concentration is respectively as follows: 108g/L, 120g/L and 143g/L, and result shows that the effect employing the invention as rat serum supplementing preparation is obvious.
Embodiment 6
Milk basic protein ferrous porphyrin composite sheet of the present invention is for the Experiment on therapy of helicobacter pylori positive anemia patient.
Selecting 80 example Helicobacter pylori Anemic patients, be divided into treatment group (40 example) and matched group (40 example), treatment group uses the chewable tablet treatment of embodiment 1, takes every day 2 times, each takes 6g；Matched group uses the common ferrous porphyrin preparation with dosage, takes 2 every day.The medicining cycle of two groups is one month, and drug withdrawal detects the concentration of hemoglobin in helicobacter pylori eradication situation and blood after 1 month.Experimental result shows: treatment group and matched group are respectively 90% and 2.5% to the eradication rate of helicobacter pylori, hemoglobin concentration is respectively 131g/L and 102g/L, treatment group curative effect is better than matched group, it was demonstrated that this chewable tablet effectively can improve anemia while eliminating pylorus.
Embodiment 7
Milk basic protein ferrous porphyrin composite sheet of the present invention is for the Experiment on therapy of common Anemic patients.
Select 80 example Anemic patients in old age, it is divided into treatment group (40 example) and matched group (40 example), treatment group uses the chewable tablet treatment of embodiment 1, take 2 every day, each taking 6g, matched group uses the ferrous porphyrin preparation with dosage, takes 2 every day, medicining cycle is one month, and drug withdrawal detected blood hemoglobin concentration after 1 month.Experimental result shows: treatment group and matched group hemoglobin concentration are respectively 127g/L and 103g/L, and treatment group curative effect is better than matched group, it was demonstrated that this chewable tablet can be effectively improved anemia.
Above-described embodiment, it can be confirmed that use milk basic protein ferrous porphyrin composite sheet of the present invention, pastes supplement relative to common ferrous sulfate supplements-iron and ferrous porphyrin, and iron supplement effect is all obviously improved；Meanwhile, this invention can effectively understand the helicobacter pylori of human body.
Although having been described for the detailed description of the invention of the present invention above, it is apparent that the various change scope without departing from claim can be made.It is to say, the technical spirit of the foundation present invention is to any simple modification made for any of the above embodiments, equivalent variations and modification, belong in the range of technical solution of the present invention.
Claims (6)
1. a milk basic protein ferrous porphyrin composite sheet, it is characterised in that main component includes milk basic protein and ferrous porphyrin.
A kind of milk basic protein ferrous porphyrin composite sheet the most according to claim 1, it is characterised in that in parts by weight, including following material: milk basic protein 1 10 parts, ferrous porphyrin 1 20 parts, maltodextrin 15 parts, potassium sorbate 15 parts, lubricant 15 parts.
A kind of milk basic protein ferrous porphyrin composite sheet the most according to claim 2, it is characterised in that described milk basic protein is for purchasing finished product.
A kind of milk basic protein ferrous porphyrin composite sheet the most according to claim 2, it is characterised in that described ferrous porphyrin is for purchasing finished product.
A kind of milk basic protein ferrous porphyrin composite sheet the most according to claim 2, it is characterised in that described lubricant is selected from one or more in Pulvis Talci, sodium stearate, magnesium stearate, adipic acid, esters of silicon acis, phosphate ester.
6. according to the preparation method of a kind of milk basic protein ferrous porphyrin composite sheet described according to any one of claim 1-5, it is characterised in that use compressing dry granulation or wet granule compression tablet to prepare.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610181004.3A CN105815658A (en) | 2016-03-28 | 2016-03-28 | Milk basic protein ferroporphyrin composite piece and preparing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610181004.3A CN105815658A (en) | 2016-03-28 | 2016-03-28 | Milk basic protein ferroporphyrin composite piece and preparing method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105815658A true CN105815658A (en) | 2016-08-03 |
Family
ID=56524295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610181004.3A Pending CN105815658A (en) | 2016-03-28 | 2016-03-28 | Milk basic protein ferroporphyrin composite piece and preparing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105815658A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101254013A (en) * | 2008-04-09 | 2008-09-03 | 北京市科威华食品工程技术有限公司 | Nourishing blood and face health care drink |
| CN101803695A (en) * | 2010-04-26 | 2010-08-18 | 北京东方红航天食品饮料有限公司 | Calcium and iron supplement product being applicable to children |
| CN103750324A (en) * | 2014-01-27 | 2014-04-30 | 泰州比尔夫生物科技有限公司 | Milk basic protein hericium erinaceus powder composite piece |
-
2016
- 2016-03-28 CN CN201610181004.3A patent/CN105815658A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101254013A (en) * | 2008-04-09 | 2008-09-03 | 北京市科威华食品工程技术有限公司 | Nourishing blood and face health care drink |
| CN101803695A (en) * | 2010-04-26 | 2010-08-18 | 北京东方红航天食品饮料有限公司 | Calcium and iron supplement product being applicable to children |
| CN103750324A (en) * | 2014-01-27 | 2014-04-30 | 泰州比尔夫生物科技有限公司 | Milk basic protein hericium erinaceus powder composite piece |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2016940B1 (en) | Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions | |
| US7994217B2 (en) | Prenatal multivitamin/multimineral supplement | |
| Ashmead | The absorption and metabolism of iron amino acid chelate | |
| CN103864950B (en) | A kind of preparation method and applications of low molecule Porphyra haitanensis polysaccharide iron complexes | |
| Maladkar et al. | A novel approach for iron deficiency anaemia with liposomal iron: concept to clinic | |
| CN101129351A (en) | Iron supplement composition, its preparing method and application of the same | |
| KR100421466B1 (en) | Manufacturing Method of Absorptive Zinc-Oligopeptide in The Human Body | |
| Biniwale et al. | Liposomal iron for iron deficiency anemia in women of reproductive age: review of current evidence | |
| CN110172106A (en) | A kind of peach gum polysaccharide iron and its application | |
| CN105815658A (en) | Milk basic protein ferroporphyrin composite piece and preparing method thereof | |
| CN1252231A (en) | Hemoglobin food series and its production process | |
| CN105688196A (en) | Chewable tablet for treating iron-deficiency anemia and preparation method thereof | |
| CA2890255C (en) | An oral iron (iii) based phosphate adsorbent for treating iron-deficiency anemia in cats with chronic kidney disease | |
| CN102948733B (en) | Production method and formula of special-eating life nutrition liquid | |
| CN102908334A (en) | Oxygen-contained capsule | |
| CN1287833A (en) | Zinc enriched medicine | |
| KR20190012943A (en) | Health functional food composition for Burning mouth syndrome and Stomatitis Treatment and Prevention | |
| CN105998059B (en) | A kind of preparation method of albumen iron iron supplementary | |
| CA2638081C (en) | Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions | |
| CN102049035B (en) | Starch polysaccharide-iron compound preparation | |
| DeWayne Ashmead | The absorption and metabolism 01 iron amino acid chelate | |
| CN1194711C (en) | Medicine 'Xuewang' for treating anemia | |
| MZ et al. | Adverse effects of fluoride towards thyroid hormone metabolism | |
| CN104207142B (en) | The preparation method of a kind of zinc supplementation and the agent of toxin expelling nutrition and health care | |
| CN1083272C (en) | Oral medicine for treating dermatosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Jingsu Inventor after: Wang Shengzhou Inventor after: Qian Yuan Inventor before: Wang Jing Inventor before: Wang Shengzhou Inventor before: Qian Yuan |
|
| COR | Change of bibliographic data | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160803 |
|
| RJ01 | Rejection of invention patent application after publication |